Article in Leukemia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
Konstantin RiegeHoffmann Group, Leibniz Institute on Aging - Fritz Lipmann Institute (FLI), Jena, Germany.
Jana LentesDepartment of Human Genetics, Hannover Medical School (MHH), Hannover, Germany.
Charlotte SchröderDepartment of Human Genetics, Hannover Medical School (MHH), Hannover, Germany.
Julia AltenDepartment of Pediatrics, Berlin-Frankfurt-Münster ALL Study Group Germany (BFM-G), University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Cornelia EckertDepartment of Pediatric Oncology and Hematology, Charité University Medical Center, Berlin, Germany.
Lara FuhrmannDepartment of Human Genetics, Hannover Medical School (MHH), Hannover, Germany.
Lennart LenkDepartment of Pediatrics, Berlin-Frankfurt-Münster ALL Study Group Germany (BFM-G), University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany.ORCID http://orcid.org/0000-0002-3916-7604
Martin SchrappeDepartment of Pediatrics, Berlin-Frankfurt-Münster ALL Study Group Germany (BFM-G), University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Brigitte SchlegelbergerDepartment of Human Genetics, Hannover Medical School (MHH), Hannover, Germany.
Gunnar CarioDepartment of Pediatrics, Berlin-Frankfurt-Münster ALL Study Group Germany (BFM-G), University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Medizinische Hochschule Hannover · DELeibniz Institute on Aging - Fritz Lipmann Institute (FLI) · DECharité - Universitätsmedizin Berlin · DEOtto-von-Guericke-Universität Magdeburg · DE
Funding
Deutsche Forschungsgemeinschaft (German Research Foundation) BE6555/1-1Deutsche Forschungsgemeinschaft (German Research Foundation) BE6555/2-1Deutsche Forschungsgemeinschaft (German Research Foundation) HO5281/1-1
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Recurrent DNMT3B rearrangements are associated with unfavorable outcome in dicentric (9;20)-positive pediatric BCP-ALL. · full record | OpenQuestion